Protagonist Therapeutics
PTGX
PTGX
156 hedge funds and large institutions have $1.34B invested in Protagonist Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 60 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
8% more funds holding
Funds holding: 144 → 156 (+12)
3.11% more ownership
Funds ownership: 98.58% → 101.69% (+3.1%)
33% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 60
Holders
156
Holding in Top 10
7
Calls
$14.5M
Puts
$2.47M
Top Buyers
| 1 | +$44.8M | |
| 2 | +$34.5M | |
| 3 | +$19.2M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.6M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$9.97M |
Top Sellers
| 1 | -$27.8M | |
| 2 | -$27.6M | |
| 3 | -$18.5M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$15.4M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$9.98M |